4-isothiocyanato-2-(trifluoromethyl)benzonitrile is supplied as a pharma-grade active pharmaceutical ingredient intended for tablet, capsule, granule, and injectable product manufacture. The molecular formula is C9H4F3N2S and the molar mass is 229.20 g·mol⁻¹. The compound consists of a benzonitrile nucleus substituted at the 2-position with a trifluoromethyl group and at the 4-position with an isothiocyanato group. This substitution pattern is distinct from mono-substituted aryl isothiocyanates because two strongly electron-withdrawing groups are present on the aromatic ring. The nitrile and trifluoromethyl groups increase the electrophilic character of the isothiocyanato carbon and reduce aqueous solubility relative to the non-fluorinated 4-isothiocyanatobenzonitrile analog. The product is manufactured as the neutral crystalline solid, not as a salt or hydrate.

The dosage-form-specific grade designation, Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable, identifies a GMP-compliant material released for formulation into oral solid dosage forms and sterile injectable preparations. It is not a technical-grade reactive intermediate. Because no United States Pharmacopeia, European Pharmacopoeia, or Japanese Pharmacopoeia monograph is published for this compound, release is controlled against an in-house monograph qualified according to ICH Q6A. Supplier product codes commonly distinguish the standard oral grade, micronized oral grade, and sterile injectable grade. The micronized oral grade is controlled for particle size by laser diffraction according to ISO 13320-1:2020, while the sterile injectable grade is released with bacterial endotoxin and bioburden data suitable for aseptic processing.

Compared with the non-fluorinated 4-isothiocyanatobenzonitrile analog, the 2-trifluoromethyl substituent produces higher reversed-phase chromatographic retention and lower aqueous solubility. Compared with aliphatic isothiocyanates such as sulforaphane, the aromatic benzonitrile structure is more rigid and less volatile. These differences affect dissolution, permeability, and handling but do not establish safety or efficacy without product-specific data.

What specification limits apply to pharma-grade release?

The release specification for a non-compendial aryl isothiocyanate of this type is typically built from a combination of chromatographic purity, residual solvent, elemental impurity, water, and particle size controls. The exact acceptance limits are supplier-specific and must be verified against the current certificate of analysis. A representative testing matrix is shown below.

The assay and impurity methods are validated for specificity, linearity, accuracy, and precision according to ICH Q2(R1). The impurity method should resolve positional isomers, including the 3-isothiocyanato and 4-trifluoromethyl variants, because these isomers can have different toxicological profiles. For injectable-grade material, the endotoxin limit is derived from the maximum total daily dose and is not a fixed universal value.

Tablet, capsule, and granule manufacture begins with dry handling under controlled humidity. The isothiocyanate group is hydrolytically sensitive and can form the corresponding amine and carbonyl sulfide in the presence of water. Aqueous wet granulation is therefore avoided unless a non-aqueous binder system is justified. Direct compression and dry granulation are the preferred processing routes. Excipient compatibility is evaluated in binary mixtures stored for 4 weeks at 40°C/75% RH and 25°C/60% RH according to ICH Q1A(R2). A loss of assay greater than 5% or formation of a new unspecified impurity above 0.10% is treated as a compatibility failure. Excipients containing primary or secondary amines, thiols, or strongly alkaline surfaces should be avoided because they can accelerate isothiocyanate degradation or form thiourea adducts. Anhydrous lactose, microcrystalline cellulose, and dibasic calcium phosphate dihydrate are typical starting diluents. Colloidal silicon dioxide and sodium stearyl fumarate may be used as flow and lubrication aids.

Powder flow is characterized by angle of repose, bulk density, tapped density, and compressibility index according to USP <616>. A compressibility index above 25% generally indicates the need for dry granulation or a glidant. The API is screened through a 500 µm or finer sieve before blending to break agglomerates. Blending may be performed in a V-blender or bin blender at 10–25 rpm for 15–30 min as a starting range, with blend uniformity confirmed by USP <905>. Dry granulation is conducted on a roller compactor with monitored roll force, roll speed, and gap. Overcompaction can reduce tabletability, while undercompaction produces weak granules. Granulated material is milled and compressed on a rotary tablet press with pre-compression. Tablet breaking force is measured by USP <1217>. Dissolution testing is performed according to USP <711>; media containing 0.1–1.0% sodium lauryl sulfate may be required to achieve sink conditions, but the surfactant concentration is justified by solubility data.

Capsule filling on dosator or tamping-pin equipment is controlled by powder bed height, pin settings, and fill weight. Granules for capsule filling are controlled for particle size distribution by sieving, and oversized granules are recycled through a mill. Aqueous film coating of tablets is possible only with short exposure time and low inlet temperature; organic solvent-based coatings are preferred for moisture-sensitive isothiocyanates. Primary packaging for oral solid dosage forms should provide a low water vapor transmission rate, such as aluminum foil blister or HDPE bottles with desiccant.

When the isothiocyanate is prepared as a sterile injectable or lyophilized product

Injectable manufacturing requires a separate control strategy because the compound has limited aqueous solubility and is hydrolytically sensitive. Ready-to-use aqueous solutions are not typical unless the formulation intent is a reactive intermediate or the isothiocyanate is stabilized in a co-solvent system. Lyophilized powder in glass vials under nitrogen or vacuum is the preferred format. The fill solution is prepared in a co-solvent system such as tert-butyl alcohol, ethanol, or dimethyl sulfoxide diluted with Water for Injection. The exact composition is determined by solubility and lyophilization behavior, not by a fixed formula.

Aseptic filtration is performed through a 0.22 µm PVDF or PTFE membrane filter. The filter is integrity-tested before and after use by bubble point or diffusive flow. Compatibility is evaluated by measuring assay and impurity profile after static contact at the target concentration for up to 24 hours at manufacturing temperature. A loss of assay greater than 5% or a new impurity above 0.10% disqualifies the filter. The filling operation is conducted in an ISO 5 environment according to ISO 14644-1:2015, with viable and non-viable monitoring. Manufacturing is governed by 21 CFR 210 and 21 CFR 211.

Lyophilization cycle development uses freeze-drying microscopy or differential scanning calorimetry to determine the collapse temperature of the formulation. The primary drying shelf temperature is set below the collapse temperature, and chamber pressure is controlled to balance heat transfer and sublimation. The dried cake is stoppered under reduced pressure or nitrogen and tested for moisture by Karl Fischer, sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, and container closure integrity by USP <1207>. Residual solvent content is tested by USP <467> and must meet ICH Q3C limits.

The injectable-grade API is handled under nitrogen in an isolator or laminar flow. The dispensing suite is controlled to low humidity, with residual oxygen below 5% and dew point below -40°C for critical handling steps. The material should not be held in aqueous media at neutral to alkaline pH for prolonged periods because the isothiocyanate group hydrolyzes under these conditions. If an injectable emulsion or liposome is considered, the formulation scientist should evaluate possible covalent reaction with phospholipid headgroups containing free amino groups.

Comparative impurity and handling profile

Relative to 4-isothiocyanatobenzonitrile, the 2-trifluoromethyl derivative has higher lipophilicity and lower aqueous solubility. The electron-withdrawing trifluoromethyl group increases the reactivity of the isothiocyanate carbon toward nucleophiles, which has direct implications for aqueous stability and covalent adduct formation. The nitrile and isothiocyanate groups give characteristic infrared bands near 2230 cm⁻¹ and 2050–2150 cm⁻¹, respectively, and these features are used to distinguish the product from structural isomers. Chromatographic purity methods must separate the 2,4-substituted compound from its positional isomers because substitution at the 3- or 5-position can alter reactivity and impurity toxicity.

Pharma-grade material differs from technical-grade aryl isothiocyanate by the absence of unidentified process-related impurities above ICH Q3A thresholds. The synthesis may introduce hydrolyzed amine, symmetric thiourea dimers, residual starting material, and residual thiophosgene-related species. A risk assessment under ICH M7 is required for potential mutagenic impurities, and the batch release documentation should include the specific control strategy. Bulk storage at 2–8°C under nitrogen in double polyethylene bags inside aluminum foil laminate minimizes water uptake. The retest period is assigned from ICH Q1A stability data. If the material is exposed to ambient humidity above 40% RH for more than 2 hours during dispensing, requalification for water and related substances is recommended because the NCS group hydrolyzes.

Published data for this specific derivative’s aqueous degradation kinetics and oral bioavailability are limited. Preformulation studies are therefore required before defining a control strategy for a given dosage form. The absence of a public monograph means that the in-house release specification should be reviewed against the proposed dose, route, and manufacturing process rather than adopted from a supplier template.